SalioGen is advancing a new category of genetic medicine we call Gene Coding, which works by adding a new genomic code to turn on, off or modify the functions of new or existing genes. We are advancing potentially curative therapies, with an initial focus on developing durable, safe and accessible genetic medicine to more patients with inherited disorders. At SalioGen, we are driven not only by our efforts to realize the immense potential of our science, but also by our dedication and commitment to developing medicines that can make a significant impact on patients’ lives.
Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
Looking ahead, SalioGen plans to explore Gene Coding’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing with the goal of helping an even broader population of patients in need.
Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
Looking ahead, SalioGen plans to explore Gene Coding’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing with the goal of helping an even broader population of patients in need.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $115M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 31.12.2022 | PBM Capita... | pbmcap.com |
| - | Retinal De... | retinaldeg... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.01.2022 | Series B | $115M | - |
Mentions in press and media 4
| Date | Title | Description |
| 21.08.2024 | Glenmark and SalioGen: A New Era in Ophthalmic Treatments | In the bustling world of pharmaceuticals and biotechnology, two companies are making waves in the ophthalmic sector. Glenmark Therapeutics Inc. and SalioGen Therapeutics are not just players; they are pioneers. Their recent announcements re... |
| 19.08.2024 | SalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical Officer | -Dr. Stasi brings to SalioGen 30 years of experience in ophthalmology and genetic medicine- LEXINGTON, Mass., Aug. 19, 2024 /PRNewswire/ -- SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on... |
| 05.01.2022 | VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases | SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech has raised another $115 million to fund its vision of the future of genetic medicines. The series ... |
| 05.01.2022 | VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases | SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech has raised another $115 million to fund its vision of the future of genetic medicines. Investors s... |